1
The Medical Guesswork Problem
The Centers for Disease Control (CDC), headquartered in Atlanta, is a national treasure. Staffed by a cadre of highly trained, dedicated professionals, the CDC protects the nation against dangerous health threats by detecting new germs as they spread around the globe, uncovering the most effective ways to combat disease, and disseminating new knowledge to physicians, policy makers and communities. The CDC sits alongside other crown jewels of Americaâs medical system, including top private and nonprofit hospitals across the nation, such as Sloan Kettering. It is no wonder that the dominant impression is that the quality of American medical care is the best in the worldââa utopia of high-tech treatments, cutting-edge research, and expeditious and effective interventions.â1
The best American medicine is indeed excellent, and the nation is unambiguously a world leader in some areas. Yet much of the care that patients receive is not particularly effective for their clinical conditions. Moreover, the United States spends dramatically more per capita on medical care than do other advanced democracies and does not consistently outperform peers on quality measures or health outcomes.2
For reasons that remain unclear, health care cost growth has moderated since 2002. Some experts suggest that possible explanations include âthe rise in high-deductible insurance plans, state-level efforts to control Medicaid costs, and a general slowdown in the diffusion of new technology, particularly in the Medicare population.â3 Yet health care costs are projected to grow at GDP plus 1.2 percent over the next twenty years, a rate high enough to cause serious pain for taxpayers and workers.4
As figure 1.1 shows, in 2013 per capita spending on medical care in the United States (including out of pocket costs, insurance payments, and taxes to pay for health programs like Medicare) was $8,617ânearly double the Organisation for Economic Co-operation and Development (OECD) average. The United States is wealthier than other nations, so it would be expected to spend more on medical care. Yet the United States also spends substantially more than peer nations, even though we have fewer physicians (and fewer physician consultations) relative to the population than other nations.5 This higher level of spending does not appear to produce consistently better results on health indicators such as life expectancy. To be sure, the United States has higher obesity and poverty rates than many European countries. But multivariate analysis that controls for income, environmental quality, and lifestyle across developed nations finds little connection between spending and health outcomes.6 Some experts believe that the U.S. medical system is distinctively inefficient.7 As economists Henry J. Aaron and Paul B. Ginsburg write, âWhatever the reason, it is hard to avoid the conclusion that the United States is buying less health than other nations do with its high outlays.â8
It is critical to distinguish between the total benefits of greater health spending over time and the benefits of extra health spending at the margin. Over time, new technologies are developed, and some of them are associated with substantial improvements in health outcomes. For example, the mortality rate from cardiovascular disease has declined by more than 50 percent since 1950, at least partly because of the development of better ways to treat heart disease.9 At any given moment, however, the knowledge about how to treat different conditions is fairly similar across developed countries. The key issues are âhow much the technology is used and how much is paid for it. By comparison with other countries, the United States uses technology in lower value settings and pays more for the same care.â10 This pattern likely stems from a combination of factors, including the absence of overall budgetary limits and supply-side constraints on medical capital equipment.11 In sum, all advanced democracies struggle with the cost and efficiency of health care delivery. However, the United States faces special challenges. Our financing and delivery systems are an unusually complex, decentralized, highly commercialized admixture of public and private plans that lack both the discipline of efficient markets and the authority of government control.
FIGURE 1.1. Health spending per capita (in US$) and as a percentage of GDP, 2013. Source: OECD Health expenditure and financing data (http://stats.oecd.org/Index.aspx?DataSetCode=SHA).
Most experts agree that a substantial portion of the U.S. medical outlay is spent inefficiently, leading to little improvement in quality or outcomes. The Institute of Medicine estimates that as much as one-third of overall U.S. medical spending is wasted annually.12 The United States spends $2.5 trillion annually in health care, so this corresponds to over $750 billion in waste each yearâmore than the budget for the Department of Defense.13
As health economist David Cutler argues, waste is marbled throughout the health delivery system, making it hard to cut out.14 It comes in many forms, including excessive administrative costs, inflated prices, fraud, andâof especial concern in our analysisâovertreatment.15 Overtreatment includes âcare that is rooted in outmoded habits, that is driven by providersâ preferences rather than those of informed patients, that ignores scientific findings, or that is motivated by something other than provision of optimal care for a patient.â16 According to some estimates, overtreatment added between $158 billion and $226 billion in wasteful spending in 2011.17 No area of medicine is immune. Overtreatment exposes patients to treatments that offer little or no health benefits as well as potential harms. Sometimes entire classes of care are inappropriate, but overtreatment also arises when a given treatment is used more intensively than clinical conditions warrant. An example is using back surgery as a first-line therapy for patients with simple cases of back pain/discomfort who would benefit from much less invasive procedures, such as drugs or physical therapy.18
Consider this puzzling situation. According to a CDC study, every year about 60 percent of American women who have had a total hysterectomy and lack a cervix receive a Pap test for cervical cancer. While there are some posthysterectomy women who need to continue screening (such as those whose surgery was done to remove cancer), the number is small. As one obstetrician stated, âItâs tough to get cervical cancer without a cervix.â19 According to the CDC, âthe net benefits of screening some women, particularly women who have undergone hysterectomy⊠might be outweighed by the net harm (e.g., false-positive tests leading to needless patient anxiety and invasive procedures).â20 The U.S. Preventive Services Task Force, the American Congress of Obstetricians and Gynecologists, and American Cancer Society all recommend against Pap tests for posthysterectomy women over the age of 30.21 Yet despite the scientific consensus against routine screening for cervical cancer posthysterectomy, the proportion of women over 30 years of age who have had a hysterectomy and recently have been screened declined only 15 percentage points between 2002 and 2010 (figure 1.2).
Screening posthysterectomy women for cervical cancer points to a larger problem. Harvard Medical School researchers analyzed Medicare claims data, looking at 26 tests and procedures that empirical research has shown not to be beneficial for patients. They found that at least one in fourâ25 percent ofâMedicare recipients received one or more of those services in 2009. The 26 services âare just a small sample of the hundreds of services that are known to provide little or no medical value to patients.â22 âWe suspect this is just the tip of the iceberg,â said study author J. Michael McWilliams.23
Millions of Americans receive antibiotics, MRIs, blood tests, diagnostic screenings, and surgeries they donât need.24 Atul Gawande, a general surgeon who has been at the vanguard of the EBM movement, reports that he took a look at eight new patients who entered his clinic one afternoon. All had medical records complete enough to permit him to review their histories. Gawande found that seven of the eight had received unnecessary care. Two had expensive diagnostic tests of no value. A third patient had undergone a questionable surgery for a lump (which the surgery failed to remove). Four patients âhad undergone inappropriate arthroscopic knee surgery for chronic joint damage.â25 These results occurred at one of the most prestigious and sophisticated medical institutions in the world. All these unnecessary treatments not only increase costs, but they can also imperil health by exposing patients to a higher risk of side effects and medical errors.26 âWhatâs remarkable is how much we do with so little evidence to support what we do, especially when it comes to the patient right in front of us,â said Harlan Krumholz, a cardiologist at Yale University.27 As David Epstein wrote in an Atlantic magazine article, âWhen Evidence Says No, but Doctors Say Yesâ:
FIGURE 1.2. Percentage of women who had a recent Papanicolaou (Pap) test (within 3 years), by hysterectomy status and age group. Behavioral Risk Factor Surveillance System, United States, 2000â2010. Note: Even years only. All trends are statistically significant using linear test of trend [p<0.05]. Percentages are weighted to the noninstitutionalized, U.S. civilian population. â 2002 American Cancer Society, 2003 American College of Obstetricians and Gynecologists, and 2003 U.S. Preventive Services task Force Pap test guidelines published. Source: Center for Disease Control and Prevention, 2013, âCervical Cancer Screening among Women by Hysterectomy Status and among Women Aged â„ 65 YearsâUnited States, 2000â2010,â Morbidity and Mortality Weekly Report 61 (51) (January 4): 1043â47, https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6151a3.htm, accessed March 15, 2017.
For all the truly wondrous developments of modern medicineâimaging technologies that enable precision surgery, routine organ transplants, care that transforms premature infants into perfectly healthy kids, and remarkable chemotherapy treatments, to name a fewâit is distressingly ordinary for patients to get treatments that research has shown are ineffective or even dangerous. Sometimes doctors simply havenât kept up with the science. Other times doctors know the state of play perfectly well but continue to deliver these treatments because itâs profitableâor even because theyâre popular and patients demand them. Some procedures are implemented based on studies that did not prove whether they really worked in the first place. Others were initially supported by evidence but then were contradicted by better evidence, and yet these procedures have remained the standards of care for years, or decades.28
We live in an age of Big Government. There is no shortage of federal rules that govern the health care sector, and agencies like the Food and Drug Administration are among the most powerful and best known regulatory agencies in the world.29 Americans could be excused if they believe (without thinking much about it) that existing regulatory frameworks ensure that new treatments enter into clinical practice only after...